Becton, Dickinson and Company ( BDX Quick Quote BDX - Free Report) , also known as BD, reported fourth-quarter fiscal 2020 adjusted earnings per share (EPS) of $2.79, which beat the Zacks Consensus Estimate of $2.50 by 11.6%. The bottom line however dropped 15.7% on a year-over-year basis and fell 15.1% at constant currency (cc).
For fiscal 2020, adjusted EPS came in at $10.20, which beat the Zacks Consensus Estimate by 3%. However, the figure fell 12.7% year over year.
For the quarter, the company raked in revenues of $4.78 billion, beating the Zacks Consensus Estimate by 6.7%. Also, the figure grew 4.4% from the year-ago quarter on a reported and currency-neutral basis.
For fiscal 2020, revenues totaled $17.11 billion, beating the Zacks Consensus Estimate by 1.7%. However, the figure fell 1% year over year.
Segment Details BD Medical
In the quarter under review, the company reported worldwide revenues of $2.32 billion, down 4.9% from the year-ago quarter, both on a reported basis and at cc. Per management, the downside can be attributed to BD Alaris System remediation in the Medication Management Solutions unit and the impact of COVID-19 across the segment. However, sustained robust performance in the Pharmaceutical Systems unit partially offset the downside.
BD Life Science
Worldwide revenues in the segment totaled $1.49 billion, up 31.2% year over year and 31.4% at cc. Per management, the upside was driven by strong sales associated with COVID-19 diagnostic testing solutions in the Diagnostic Systems unit on the BD Veritor and BD Max platforms.
This segment generated worldwide revenues of $0.98 billion, down 3.4% from the year-ago quarter and 3.5% at cc. This was due to the impact of COVID-19 on the segment.
In the fiscal third quarter, revenues in the United States grew 7.4% to $2.75 billion. Per management, solid performance in the United States reflects higher sales associated with COVID-19 testing solutions in the Diagnostic Systems unit on the BD Veritor and BD Max platforms. However, expected decline in the Medication Management Solutions unit due to the BD Alaris System remediation partially offset the upside.
Revenues outside the United States grossed $2.03 billion, up 0.5% from the year-ago quarter, both on reported and currency-neutral basis. Per management, this upside was driven by strong performance in Europe, which was partially offset by declines in China, EMA and Latin America.
In the fiscal fourth quarter, gross profit amounted to $2.2 billion, down 2.6% from the prior-year quarter tally. Gross margin was 46.1%, down 332 bps from the prior-year quarter.
Adjusted operating profit amounted to $707 million, down 21.6% from the year-ago figure. Adjusted operating margin was 14.8%, down 490 bps.
The company exited fiscal 2020 with cash and equivalents amounting to $2.83 billion, compared with $536 million in the year-ago period. Cumulative net cash provided by operating activities came in at $3.54 billion, compared with $3.33 billion in the year-ago period.
Fiscal 2021 Guidance
For 2021, revenues are projected to grow high single to low double-digits percentage rate. The Zacks Consensus Estimate for the same is pegged at $18.80 billion.
Full fiscal 2021, adjusted EPS is estimated between $12.40 and $12.60. This suggests growth of almost 21.5% to 23.5% compared to the prior fiscal year. The Zacks Consensus Estimate for the same is pegged at $12.53.
BD exited fiscal 2020 on a strong note. Within the United States, the Diagnostic Systems unit witnessed strong revenue growth due to COVID-19 testing. The company continues to see solid demand for its product portfolio that supports the global COVID-19 response, especially the recent launch of its COVID-19 rapid point-of-care antigen test. The company saw revenue growth in the BD Life Science segment
. Both domestic and international revenues increased year over year in the quarter under review. A plethora of recent regulatory approvals instill optimism.
However, decline across the other two core segments during the quarter is concerning. Contraction in gross and adjusted operating margins raises concern. Unfavorable foreign currency impacted BD’s quarterly bottom line.
Zacks Rank and Key Picks
BD currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space that have announced their quarterly results are
Thermo Fisher Scientific Inc. ( TMO Quick Quote TMO - Free Report) , Align Technology, Inc. ( ALGN Quick Quote ALGN - Free Report) and AngioDynamics, Inc. ( ANGO Quick Quote ANGO - Free Report) . While Align Technology currently sports a Zacks Rank #1 (Strong Buy), the other two carry a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here .
Thermo Fisher reported third-quarter 2020 adjusted EPS of $5.63, beating the Zacks Consensus Estimate by 28.8%. Revenues of $8.52 billion surpassed the consensus mark by 10%.
Align Technology reported third-quarter 2020 adjusted EPS of $2.25, which surpassed the Zacks Consensus Estimate by 281.4%. Revenues of $734.1 million outpaced the consensus mark by 38%.
AngioDynamics reported first-quarter fiscal 2021 adjusted EPS of 2 cents against the Zacks Consensus Estimate of a loss per share of 6 cents. Revenues of $70.2 million beat the consensus mark by 6.9%.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>